• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.

作者信息

van Hazel G A, Scott M, Rubin J, Moertel C G, Eagan R T, O'Connell M J, Kovach J S

出版信息

Cancer Treat Rep. 1983 Sep;67(9):805-10.

PMID:6411337
Abstract

We have characterized plasma pharmacokinetics in 30 patients receiving mitomycin C (mitomycin) in doses ranging from 6 to 20 mg/m2 by iv bolus injection, either alone or in combination with other chemotherapeutic drugs. Plasma elimination of the drug was described by a two-compartment model in all but three cases, giving mean values for alpha-half-life of 8.2 mins, beta-half-life of 51.8 mins, and total body clearance of 332.9 ml/min/m2. The mean urinary excretion was 8.1% of the total dose administered. We did not detect alterations in pharmacologic parameters related to liver dysfunction, dose of mitomycin, and concomitant administration of other cytotoxic drugs.

摘要

相似文献

1
Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
Cancer Treat Rep. 1983 Sep;67(9):805-10.
2
Pharmacokinetics of mitomycin C in humans.丝裂霉素C在人体中的药代动力学。
Cancer Res. 1983 Oct;43(10):5017-21.
3
[Pharmacokinetics of mitomycin C in cancer patients during prolonged administration of the preparation].[丝裂霉素C在制剂长期给药期间癌症患者体内的药代动力学]
Antibiotiki. 1984 May;29(5):391-3.
4
[A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
Gan To Kagaku Ryoho. 1985 Sep;12(9):1787-93.
5
[Blood levels of mitomycin C in patients given by various routes of administration].[不同给药途径患者的丝裂霉素C血药浓度]
Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 1):2639-44.
6
Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.对晚期实体瘤患者单次静脉推注吡嗪 - 2 - 重氮氢氧化物的I期评估及药代动力学研究。
Cancer Res. 1993 Oct 15;53(20):4843-9.
7
Pharmacokinetics of mitomycin C in dogs: application of a high-performance liquid chromatographic assay.丝裂霉素C在犬体内的药代动力学:高效液相色谱分析法的应用
J Pharm Sci. 1984 Sep;73(9):1220-3. doi: 10.1002/jps.2600730909.
8
NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).齐多夫定(CAS编号:30516-87-1)及齐多夫定/α-干扰素对B6C3F1雄性小鼠的毒理学与致癌性研究(灌胃研究)
Natl Toxicol Program Tech Rep Ser. 1999 Feb;469:1-361.
9
Distribution and excretion of 7-N-(p-hydroxyphenyl)-mitomycin C in normal mice.7-N-(对羟基苯基)丝裂霉素C在正常小鼠体内的分布与排泄
Gan. 1982 Aug;73(4):675-80.
10
Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung.丝裂霉素C在非小细胞肺癌中的药代动力学。
Cancer Chemother Pharmacol. 1984;13(1):1-4. doi: 10.1007/BF00401436.

引用本文的文献

1
Safety of BromAc with Mitomycin C during hyperthermic intraperitoneal chemotherapy (HIPEC): a preclinical study.丝裂霉素C联合溴己新在腹腔热灌注化疗(HIPEC)中的安全性:一项临床前研究。
Am J Cancer Res. 2025 Mar 15;15(3):1213-1223. doi: 10.62347/HQJH9945. eCollection 2025.
2
Intraperitoneal hyperthermic chemotherapy: experience at Baylor University Medical Center.腹腔内热化疗:贝勒大学医学中心的经验
Proc (Bayl Univ Med Cent). 2002 Oct;15(4):359-62. doi: 10.1080/08998280.2002.11927864.
3
Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.
World J Urol. 1996;14 Suppl 1:S8-11. doi: 10.1007/BF00182057.
4
Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer.在一项针对晚期胃肠道癌患者的1期研究中联合给予BW12C和丝裂霉素C的药代动力学。
Cancer Chemother Pharmacol. 1993;32(1):67-72. doi: 10.1007/BF00685879.
5
Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study.持续高温腹腔灌注预防胃癌腹膜复发:随机对照研究
World J Surg. 1994 Jan-Feb;18(1):150-5. doi: 10.1007/BF00348209.
6
Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.
Cancer Chemother Pharmacol. 1988;22(2):104-8. doi: 10.1007/BF00257305.
7
Relationship between clinical parameters and pharmacokinetics of mitomycin C.丝裂霉素C的临床参数与药代动力学之间的关系
J Cancer Res Clin Oncol. 1987;113(1):91-4. doi: 10.1007/BF00389973.
8
Absence of interaction between furosemide and mitomycin C.呋塞米与丝裂霉素C之间无相互作用。
Cancer Chemother Pharmacol. 1987;19(1):84-6. doi: 10.1007/BF00296263.
9
The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy.丝裂霉素C单药使用或作为联合化疗一部分使用时的药代动力学差异。
J Cancer Res Clin Oncol. 1986;112(3):283-4. doi: 10.1007/BF00395925.
10
Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones.过氧化氢和羟基自由基的形成在抗癌醌类物质杀伤艾氏腹水癌细胞中的作用
Proc Natl Acad Sci U S A. 1986 Jun;83(12):4514-8. doi: 10.1073/pnas.83.12.4514.